This is an author produced version of a paper published in Cancer Epidemiology, Biomarkers & Prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Citation for the published paper:

"Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers."
Original Paper

Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers


* Christoph Engel and Beatrix Versmold contributed equally to this work
1 Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Germany
2 Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology (CIO), University of Cologne, Germany
3 Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec, Canada
4 Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
5 Department of Oncology, University of Cambridge, UK
6 Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
7 Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, UK
8 Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, UK
9 Department of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter, UK
10 Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge
11 INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France
12 Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France
13 Equipe labellisée LIGUE 2008, UMR5201 CNRS, Centre Léon Bérard, Université de Lyon, Lyon, France
14 Centre Antoine Lacassagne, Nice, France
15 Centre Hospitalier Universitaire, Grenoble, France
16 Institut Claudius Regaud, Toulouse, France
17 Centre Jean Perrin, Clermont-Ferrand, France
18 Department of Obstetrics and Gynaecology, Technical University Munich, Germany
19 Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Germany
20 Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany
21 Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Germany
Institute of Human Genetics, University of Münster, Münster, Germany
Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany
Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany
Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany
Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany
Queensland Institute of Medical Research, Brisbane, Australia
Peter MacCallum Cancer Centre, Melbourne, Australia
Dept of Oncology, Clinical Sciences, Lund University, S-22185 Lund, Sweden
Dept of Clinical Genetics, Lund University, S-22185 Lund, Sweden
Dept of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, S-75185 Uppsala, Sweden
Dept of Oncology, Karolinska Institutet, Karolinska University Hospital, S-17176 Stockholm, Sweden
Swedish Breast Cancer Study, Sweden (see Acknowledgements)
Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands
Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands
Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands
HEereditary Breast and Ovarian cancer group Netherlands (HEBON)
University of Pennsylvania
Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center (CNIO) Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Spain
Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Molecular Diagnostics Lab, IRRP, NCSR 'Demokritos', 15310 Agia Paraskevi, GREECE
The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel
Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel
Clinical Genetics Branch, US National Cancer Institute, Bethesda MD, USA
Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland
Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA
Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain
Corresponding author:

Prof. Rita K. Schmutzler, MD

Centre of Familial Breast and Ovarian Cancer

University Hospital of Cologne

Kerpener Strasse 34

50931 Cologne, Germany

Phone: +49 221 478-86509

Fax: +49 221 478-86510

E-mail: rita.schmutzler@uk-koeln.de

Running Head: CASP8 D302H and CASP10 V410I in BRCA1/2 Mutation Carriers
Abstract

Background: The genes caspase-8 (CASP8) and caspase-10 (CASP10) functionally cooperate and play a key role in the initiation of apoptosis. Suppression of apoptosis is one of the major mechanisms underlying the origin and progression of cancer. Previous case-control studies have indicated that the polymorphisms CASP8 D302H and CASP10 V410I are associated with a reduced risk of breast cancer in the general population.

Methods: In order to evaluate whether the CASP8 D302H (CASP10 V410I) polymorphisms modify breast or ovarian cancer risk in BRCA1 and BRCA2 mutation carriers, we analyzed 7,353 (7,227) subjects of white European origin provided by 19 (18) study groups that participate in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). A weighted cohort approach was used to estimate hazard ratios (HRs) and 95% confidence intervals (95%CIs).

Results: The minor allele of CASP8 D302H was significantly associated with a reduced risk of breast cancer (per allele HR 0.85, 95%CI 0.76-0.97, p-trend=0.011) and ovarian cancer (per allele HR 0.69, 95%CI 0.53-0.89, p-trend=0.004) for BRCA1 but not for BRCA2 mutation carriers. The CASP10 V410I polymorphism was not associated with breast or ovarian cancer risk for BRCA1 or BRCA2 mutation carriers.

Conclusions: CASP8 D302H decreases breast and ovarian cancer risk for BRCA1 mutation carriers but not for BRCA2 mutation carriers.

Impact: The combined application of these and other recently identified genetic risk modifiers could in the future allow better individual risk calculation and could aid in the individualized counselling and decision making with respect to preventive options in BRCA1 mutation carriers.
Introduction

Caspase-8 encoded by the *CASP8* gene (OMIM 601763; Chromosome 2q33) is an apical caspase involved in receptor-induced apoptosis. Caspase-10, encoded by the *CASP10* gene (OMIM 601762; Chromosome 2q33) adjacent to *CASP8* in the human genome, cooperates with caspase-8 in the transduction of death-receptor mediated apoptotic signals. In addition to deregulated cell proliferation, suppression of apoptosis is one of the major mechanisms underlying the origin and progression of cancer (1-3). Although occurring at low frequencies, inactivating mutations in *CASP8* as well as *CASP10* have been identified in different tumor types (4-6). In addition, several coding polymorphisms in selected apoptotic genes, including *CASP8* and *CASP10*, have been investigated with regard to their effect on cancer risk (7-16). Three independent studies found significant associations between the coding variant D302H in *CASP8* (rs1045485) and reduced sporadic breast cancer risk (7, 9, 13). In addition, the largest of these studies performed on 16,423 cases and 17,109 controls within the Breast Cancer Association Consortium, revealed no associations between the variant and age of onset, hormone receptor status, grade, stage or history of breast cancer in first-degree female relatives (13).

In case-control studies on patients selected for a family history of breast cancer, Frank et al. investigated the effect of the two coding polymorphisms *CASP8* D302H (rs1045485) and *CASP10* V410I (rs13010627) on breast cancer risk (9, 10). While there was no significant association between the *CASP8* 302H allele and breast cancer risk, carriers of the *CASP10* 410I allele were at a significantly reduced risk of breast cancer (odds ratio, OR=0.62, 95% confidence interval, 95%CI=0.43-0.88, \( p_{\text{trend}}=0.0039 \)). The breast cancer risk was found to be even lower for individuals who also carried the *CASP8* H302 allele (OR=0.35, \( p_{\text{trend}}=0.007 \)).
The associations between these variants and cancer risk for BRCA1 and BRCA2 mutation carriers have not been previously investigated. In the present paper we used data from the Consortium of Investigator of Modifiers of BRCA1/2 (CIMBA) to evaluate the associations the CASP8 D302H and CASP10 V410I variants and breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.
Materials and Methods

Study population. Female $BRCA1$ and $BRCA2$ mutation carriers over the age of 18 years were identified through 19 clinical and population-based research groups mainly from Europe, North America and Australia. This work was done within the framework of the Consortium of Investigators of Modifiers of $BRCA1/2$ (CIMBA). CIMBA is an international collaboration which was established in 2005 to conduct collaborative analyses of genetic polymorphisms as modifiers of cancer risk in $BRCA1$ and $BRCA2$ mutation carriers using sample sizes large enough to provide sufficient power to detect even moderate effects (17). Recruitment of subjects was approved by institutional review boards or ethics committees at all sites. Eligibility was restricted to individuals who were carriers of clearly pathogenic mutations according to defined criteria (http://research.nhgri.nih.gov/rojects/bic/) (18). Phenotype data included year of birth, $BRCA$ mutation description, ethnicity, country of residence, age at last follow-up, ages at breast and ovarian cancer diagnosis, age at bilateral prophylactic mastectomy, and age at bilateral prophylactic oophorectomy.

Genotyping. Samples from seven centres were genotyped at the Queensland Institute of Medical Research for the $CASP8$ and $CASP10$ SNPs using the iPLEX technology. The remaining centres used TaqMan allelic discrimination assays (13, 19). The TaqMan PCR primers were 5’-ACCACGACCTTTGAAGAGCTT-3’ (forward) and 5’-GTGGTCCATGAGTTGATTTTCA-3’ (reverse) for the $CASP8$ analysis and 5’-GGCCTGCAAGGTGAAGAG-3’ (forward) and 5’-GCCTGCTCAGGGTTCAAGA-3’ (reverse) for the $CASP10$ analysis. The probe for the $CASP8$ C allele was FAM-5’-CCCCACCATGACTG-3’ and for the $CASP8$ G allele was VIC-5’-CCCCACGCTAGACTG-3’. For the $CASP10$ analysis the probe for the A allele was FAM-5’-CAGCCTTCATGCCAAGAG-3’ and for the G allele was VIC-5’-CAGCCTTCCGTATCC-3’. All of the rare $CASP8$
homozygotes (CC) were confirmed by sequencing using the following primers: 5’-GTGCTCTCCAGCTGTGGTC-3’ (forward) and 5’-CCAGTGAACTGACATGTCAGC-3’ (reverse).

The DKFZ samples were genotyped using PCR-based RFLP analyses. *CASP8* D302H was genotyped using newly designed 5’-GCTTTGACCACGACCTTTGAAG-3’ (forward) and 5’-GTTACTGTGGTCCATGAGTTGGTAGAT-3’ (reverse) primers. The reaction was set up in 10 µl containing 25 ng genomic DNA, 1x PCR buffer (Qiagen, Hilden, Germany), 3.5 mM MgCl2, 0.2 µM of each primer, 200 µM of each dNTP (Promega, Mannheim, Germany), and 0.4 U HotStarTaq DNA polymerase (Qiagen, Hilden, Germany). After an initial denaturation step for 15 min at 95°C, 35 cycles of PCR reactions consisting of 1 min. at 94°C, 1 min. at 62°C and 1 min. at 72°C were carried out, which were followed by a final extension step for 10 min at 72°C. PCR products were digested with 4 U *Hsp*92II (Promega GmbH, Mannheim, Germany) and separated on a 3.5% agarose gel containing ethidium bromide (Sigma-Aldrich, Steinheim, Germany) and scored by UV visualization. Sizes of the labelled fragments were 102 bp and 12 bp for the G allele and 52 bp, 50 bp and 12 bp for the C allele. *CASP10* V410I was also genotyped with PCR-based RFLP analyses using newly designed 5’-GATCATGTCTCACTTCACAG-3’ (forward) and 5’-AAGTGGGTGCCTGCTCAG-3’ (reverse) primers. PCR reactions and conditions were as for the *CASP8* D302H analysis, with the exception of using 2.5 mM MgCl2 and amplifying by 35 cycles of 30 sec. at 94°C, 30 sec. at 56°C and 30 sec. at 72°C. PCR products were digested with 2.5 U *Bfu*I (Fermentas, St. Leon, Germany), separated on a 2.5% agarose gel containing ethidium bromide (Sigma-Aldrich, Steinheim, Germany) and scored by UV visualization. Fragment sizes were 112 bp and 34 bp for the G allele and 146 bp for the A allele.

To ensure consistency in genotyping across studies, all genotyping centres had to adhere to the CIMBA genotyping quality control criteria: for each study site, a call rate of over 95%
after exclusion of samples that failed amplification of both SNPs, was required. At least 2% of the samples had to be included in duplicate and every plate had to be composed of no template controls and random mixture of affected and unaffected carriers. The concordance among duplicates had to be at least 98%. To further validate the accuracy of genotyping across centres, all centres were required to genotype 95 DNA samples from a standard test plate (Coriell Institute, Camden, New Jersey, USA) for the CASP8 D302H SNP. Details of the CIMBA quality control guidelines are publicly available (http://www.srl.cam.ac.uk/consortia/cimba/eligibility/eligibility.html).

**Patient selection:** Of 8,890 cases genotyped for CASP8 we excluded 218 cases because they failed genotyping quality control, 35 because they were ascertained by more than one study group, 71 because of insufficient documentation of pathogenic BRCA mutations, 17 because date of birth was not available, nine because of missing data on age at last observation or age under 18 years, 202 because of non-Caucasian origin and 985 because of significant deviation from Hardy-Weinberg-Equilibrium in two study groups. The remaining 7,353 cases were analysed as described below.

Of 7,842 cases genotyped for CASP10 we excluded 246 cases because they failed genotyping quality control, 35 because they were ascertained by more than one study group, 73 because of insufficient documentation of pathogenic BRCA mutations, 17 because date of birth was not available, 9 because of missing data on age at last observation or because they were under 18 years old and 235 because of non-caucasian origin. The remaining 7,227 cases were analysed as described below.

**Statistical analysis.** Deviations of observed from expected genotype frequencies under the Hardy-Weinberg equilibrium were assessed among unrelated carriers within each contributing
study group using an exact test. Study groups showing a significant deviations of p<0.005 were excluded from further analysis. As a result, data from two study groups were excluded from the CASP8 D302H analysis.

The associations between CASP8 D302H or CASP10 V410I genotype and breast or ovarian cancer risk data were analyzed within a Cox proportional hazards framework. To adjust for the non-random sampling of mutation carriers with respect to their disease status, we analysed the data using a weighted cohort approach as described elsewhere (20, 21). This involves assigning differential weights to affected and unaffected mutation carriers such that the breast or ovarian cancer incidence rates observed in the study population are consistent with established BRCA1 and BRCA2 incidences (22). Subjects were followed from birth until the event of interest (first breast or ovarian cancer) or time of censoring. When analyzing breast cancer as the event of interest, subjects without breast cancer were censored at bilateral mastectomy, ovarian cancer, or last observation, whichever occurred first. When ovarian cancer was analyzed, subjects without ovarian cancer were censored at bilateral oophorectomy, first breast cancer, or last observation, whichever occurred first. Follow up time was censored at age 80 years old. The associations were evaluated by modelling the per-allele hazard ratio (one degree-of-freedom) and by fitting models with separate HR for the heterozygote and homozygote carriers of the minor allele (two degree-of-freedom model). Analyses were carried out separately for BRCA1 and BRCA2 mutations carriers (carriers of compound BRCA1 and BRCA2 mutations were included in the BRCA1 subgroup). Analyses were stratified by study group, country of residence (because some study groups contributed samples from more than one country) and year of birth (grouped into <1930, 1930-1939, 1940-1949, 1950-1959, 1960+). To allow for the non-independence among members of the same family, a robust variance approach was used to estimate the standard errors associated with the parameter estimates (23). The heterogeneity of hazard ratios among study groups
were tested using Cochran's Q test based on inverse variance weights. P-values equal to or smaller than 0.05 were considered statistically significant. All analyses were carried out using SPSS 15.0.1.1 (SPSS Inc.) and R 2.9.1 (The R Foundation for Statistical Computing) using the survival package version 2.35-4.
Results

A total of 7,353 and 7,227 Caucasian subjects could be analyzed for the association of CASP8 D302H and CASP10 V410I with age of onset of breast cancer or ovarian cancer. The cohort comprised 7,782 different individuals, of which 6,798 were genotyped for both SNPs, 555 for only CASP8 D302H, and 429 for only CASP10 V410I.

Tables 1 and 2 give the number of carriers by study, genotype and disease status. The overall minor allele frequencies were 0.12 (range 0.04 and 0.16) for CASP8 D302H and 0.07 (range 0.05 and 0.09) for CASP10 V410I. The mean age at breast cancer was 42 and 44 years for BRCA1 and BRCA2 mutation carriers, respectively, and the corresponding mean ages of ovarian cancer were 49 and 56 years. Table 3 shows the distribution of genotypes by SNP, mutated BRCA gene and disease status.

Tables 4 and 5 summarize the results of the association analysis. A significant association was found for BRCA1 mutation carriers ($p_{2df}=0.028$, $p_{trend}=0.011$), but not for BRCA2 mutation carriers ($p_{2df}=0.794$, $p_{trend}=0.550$). Within the BRCA1 mutation carriers, each copy of the minor allele was estimated to confer a hazard ratio (HR per-rare-allele) of 0.85 (95%CI 0.76-0.97). There was also a significant association between CASP8 D302H and ovarian cancer risk for BRCA1 mutation carriers ($p_{2df}=0.008$, $p_{trend}=0.004$), but not in the BRCA2 subgroup ($p_{2df}=0.718$, $p_{trend}=0.398$). As with breast cancer, the effect of the rare allele was protective for ovarian cancer for BRCA1 mutation carriers (HR per-rare-allele 0.69, 95%CI 0.53-0.89).

Based on the two degree of freedom test, there were no significant associations between CASP10 V410I genotype and the risk of breast or ovarian cancer. However, the per-allele effect on ovarian cancer within the BRCA2 carriers was marginally significant ($p_{trend}=0.045$) with a HR per-rare-allele of 1.78 (95%CI 1.01-3.12).
Figure 1 shows the study-specific estimates of the per-allele hazard ratio for the two analyses in which significant associations were detected. There was no significant heterogeneity between the study-specific estimates for the association of \textit{CASP8} D302H with breast cancer risk in \textit{BRCA1} carriers ($p_{\text{heterogeneity}}=0.712$). However, there was a marginally significant heterogeneity for the association of \textit{CASP8} D302H with ovarian cancer risk in \textit{BRCA1} carriers ($p_{\text{heterogeneity}}=0.048$). For one study group (MAYO), the estimate of the hazard ratio was significantly different and in the opposite direction compared to the overall CIMBA estimate (HR=6.10, 95\%CI 1.95-19.12), suggesting that the observed heterogeneity is caused by this study group. We therefore repeated the association analysis without the data from the MAYO study group. The overall association remains significant with a similar hazard ratio (HR\textit{per-rare-allele} 0.67, 95\%CI 0.51-0.86, $p_{\text{2df}}=0.003$, $p_{\text{trend}}=0.002$), but heterogeneity among study-groups is no longer present ($p_{\text{heterogeneity}}=0.625$).

An analysis of the combined per-allele effects of the two SNPs in a multiplicative (log-additive) model revealed no qualitative changes in the results regarding the main effects, i.e. the risk reducing association between \textit{CASP8} D302H and breast and ovarian cancer in \textit{BRCA1} carriers was still significant. There were no significant interactions between \textit{CASP8} and \textit{CASP10}. However, the marginally significant per-allele effect of \textit{CASP10} on ovarian cancer within the \textit{BRCA2} carriers was not seen in this combined analysis.
Discussion

In this study, we pooled data from 19 study groups worldwide to investigate the association of \( \text{CASP8} \) D302H (\( \text{CASP10} \) V410I) genotypes with breast and ovarian cancer risk in over 7,000 Caucasian carriers of deleterious mutations in \( \text{BRCA1} \) or \( \text{BRCA2} \).

We found that the minor allele of \( \text{CASP8} \) D302H was associated with a reduced risk of breast cancer (per allele HR 0.85, 95%CI 0.76-0.97) for \( \text{BRCA1} \) but not for \( \text{BRCA2} \) mutation carriers. Previously published case-control studies in unselected breast cancer cases also described a significantly decreased risk of breast cancer in carriers of the \( \text{CASP8} \) 302H allele with an OR of 0.83-0.89 (7, 13). Thus, the per-allele HR estimate for \( \text{BRCA1} \) mutation carriers in our study was consistent with the magnitude of the association in the general population. A recent paper by Palanca Suela et al. reported on an OR of 0.40 of \( \text{CASP8} \) D302H for breast cancer in a combined analysis of both \( \text{BRCA1} \) and \( \text{BRCA2} \) mutation carriers (24). This is partly consistent with our finding for \( \text{BRCA1} \) mutation carriers but not for \( \text{BRCA2} \), although they had not investigated the associations separately in \( \text{BRCA1} \) and \( \text{BRCA2} \) mutation carriers, and their study included only 186 \( \text{BRCA1} \) and 204 \( \text{BRCA2} \) mutation carriers.

The finding that \( \text{CASP8} \) D302H is not a risk modifier in both \( \text{BRCA1} \) and \( \text{BRCA2} \) carriers is consistent with previous findings for other SNPs, which also showed associations for one subgroup only (25). The differential association patterns between \( \text{BRCA1} \) and \( \text{BRCA2} \) subgroups might be explained by the fact that these groups represent pathologically distinct entities. In our study we could not analyze whether there are differences in the association by estrogen (ER) or progesterone receptor (PR) status because such data were not available at the time of analysis. Cox et al. did not find significant differences in the \( \text{CAPS8} \) rs1045485 risk association by ER or PR status of the tumors, however, the statistical power to detect such a
differences might have been too low given the weak effect and the relatively low minor allele frequency. Larger studies will aim to clarify the associations with different disease subtypes in the general population.

Our study was reasonably powered to detect an allele with a minor allele frequency of 0.13 and a per-allele relative risk (RR) of 0.88 (which are the MAF and association magnitude for \textit{CASP8} D302H observed in the general population) at a significance level of 0.05 for \textit{BRCA1} mutation carriers (power=70%), but the power was lower for \textit{BRCA2} mutation carriers (power=37%). Larger studies are needed to elucidate the role of this polymorphism in breast cancer for \textit{BRCA2} mutation carriers.

Recent haplotype analysis of the \textit{CASP8} locus provided evidence that the D302H variant is not the functionally relevant variant because a haplotype including the D302H variant could be determined that conferred a higher risk than the variant alone. This suggests that the variant cosegregates with one or even several causative variants (26).

This is the first report on a risk-reducing effect of the \textit{CASP8} D302H variant for ovarian cancer in \textit{BRCA1} mutation carriers (per allele HR 0.69, 95%CI 0.53-0.89). In contrast, there was no association between the variant and ovarian cancer in a large study comprising more than 4,600 unselected ovarian cancer cases (27), although the effect estimate was in same direction as in our study. The reason for the lack of association in the general population is not clear. Furthermore, the authors could not find significant associations with different disease subtypes. As indicated above, we could not evaluate in our study whether the association varies with disease subtype. The observed association in our study could potentially reflect a \textit{BRCA1} specific effect, but future studies with larger numbers of \textit{BRCA1}
mutation carriers with ovarian cancer should aim to evaluate this further. Palanca Suela et al. also reported a lack of association of ovarian cancer in \textit{BRCA} mutation carriers with the D302H variant (24). However, this may be due to the small study sample size as their cohort comprised only 182 affected mutation carriers without stating the exact number of patients diagnosed with breast or ovarian cancer. Latif et al. found that the D302H variant is associated with a significantly reduced risk of ovarian cancer in a case-control study including 101 women from families with familial ovarian cancer who were BRCA1/2 negative (OR=0.52, 95%CI 0.30-0.88) (28). However, they could not detect any association in 52 women from BRCA1/2 positive families, probably because of the small sample size.

The localization of the \textit{CASP10} V410I polymorphism five amino acids upstream of the proenzyme-cleavage site and seven amino acids downstream of the active-site motif rendered it an interesting SNP as well (29). In a case-control study of 511 familial breast cancer cases who did not carry \textit{BRCA1} and \textit{BRCA2} mutations and 547 controls, carriers of the \textit{CASP10} 410I allele had a significantly reduced risk of breast cancer (10). However, a large study in more than 30,000 breast cancer cases could not confirm the association of V401I with breast cancer risk in the general population (30). This is in line with our results of no association between \textit{CASP10} V410I and breast cancer risk in \textit{BRCA1} and \textit{BRCA2} mutation carriers.

The present study is the largest of its kind in \textit{BRCA1/2} mutation carriers and provides significant evidence of association between \textit{CASP8} D302H variant and breast and ovarian cancer in \textit{BRCA1} but not in \textit{BRCA2} mutation carriers. A per-allele HR of 0.85 would result in a risk difference in the absolute risk of breast cancer of approximately 11% between the common and rare homozygotes by age of 80 years. Based on the present association, this polymorphism is estimated to account for only 0.4% of the genetic variability in breast cancer.
risk for BRCA1 mutation carriers (31). Thus, the clinical utility of this single variant is limited. However, several other loci which were originally suggested as genetic risk factors in genome-wide association studies, were recently found by CIMBA to function as risk modifiers in BRCA1 and BRCA2 mutation carriers (31, 32). As further genetic modifiers of risk are identified for BRCA1 mutation carriers, the CASP8 variant in combination with others may be informative for risk assessment purposes. Furthermore, additional consideration of non-genetic risk factors may improve individualized risk prediction.
Table 1. Numbers of carriers included in the analysis (by study group and genotype)

<table>
<thead>
<tr>
<th>Study group</th>
<th>CASP8 D302H</th>
<th></th>
<th></th>
<th></th>
<th>CASP10 V410I</th>
<th></th>
<th></th>
<th></th>
<th>MAF</th>
<th></th>
<th></th>
<th>MAF</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>GG</td>
<td>CG</td>
<td>CC</td>
<td>MAF</td>
<td>Total</td>
<td>GG</td>
<td>GA</td>
<td>AA</td>
<td>MAF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNIO</td>
<td>365</td>
<td>295</td>
<td>66</td>
<td>4</td>
<td>0.10</td>
<td>370</td>
<td>332</td>
<td>37</td>
<td>1</td>
<td>0.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DKFZ</td>
<td>98</td>
<td>76</td>
<td>20</td>
<td>2</td>
<td>0.12</td>
<td>98</td>
<td>84</td>
<td>12</td>
<td>2</td>
<td>0.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA HEBON</td>
<td>420</td>
<td>335</td>
<td>83</td>
<td>2</td>
<td>0.10</td>
<td>481</td>
<td>416</td>
<td>63</td>
<td>2</td>
<td>0.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMBRACE</td>
<td>1081</td>
<td>819</td>
<td>251</td>
<td>11</td>
<td>0.13</td>
<td>1086</td>
<td>930</td>
<td>150</td>
<td>6</td>
<td>0.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FCCC</td>
<td>132</td>
<td>108</td>
<td>23</td>
<td>1</td>
<td>0.09</td>
<td>137</td>
<td>121</td>
<td>16</td>
<td>0</td>
<td>0.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GEMO</td>
<td>1270</td>
<td>968</td>
<td>266</td>
<td>36</td>
<td>0.13</td>
<td>753</td>
<td>657</td>
<td>92</td>
<td>4</td>
<td>0.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GC-HBOC</td>
<td>856</td>
<td>646</td>
<td>196</td>
<td>14</td>
<td>0.13</td>
<td>855</td>
<td>737</td>
<td>113</td>
<td>5</td>
<td>0.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCSC</td>
<td>168</td>
<td>135</td>
<td>29</td>
<td>4</td>
<td>0.11</td>
<td>168</td>
<td>151</td>
<td>14</td>
<td>3</td>
<td>0.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HEBCS</td>
<td>184</td>
<td>141</td>
<td>39</td>
<td>4</td>
<td>0.13</td>
<td>184</td>
<td>161</td>
<td>23</td>
<td>0</td>
<td>0.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>INHERIT</td>
<td>154</td>
<td>124</td>
<td>30</td>
<td>0</td>
<td>0.10</td>
<td>154</td>
<td>134</td>
<td>19</td>
<td>1</td>
<td>0.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>kConFab</td>
<td>767</td>
<td>579</td>
<td>170</td>
<td>18</td>
<td>0.13</td>
<td>764</td>
<td>635</td>
<td>125</td>
<td>4</td>
<td>0.09</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAYO</td>
<td>160</td>
<td>128</td>
<td>31</td>
<td>1</td>
<td>0.10</td>
<td>162</td>
<td>142</td>
<td>19</td>
<td>1</td>
<td>0.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCI</td>
<td>188</td>
<td>148</td>
<td>37</td>
<td>3</td>
<td>0.11</td>
<td>195</td>
<td>170</td>
<td>24</td>
<td>1</td>
<td>0.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCGN</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>306</td>
<td>263</td>
<td>43</td>
<td>0</td>
<td>0.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PBCS</td>
<td>81</td>
<td>63</td>
<td>16</td>
<td>2</td>
<td>0.12</td>
<td>84</td>
<td>75</td>
<td>9</td>
<td>0</td>
<td>0.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMC</td>
<td>345</td>
<td>317</td>
<td>28</td>
<td>0</td>
<td>0.04</td>
<td>334</td>
<td>304</td>
<td>29</td>
<td>1</td>
<td>0.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SWE-BRCA</td>
<td>537</td>
<td>411</td>
<td>119</td>
<td>7</td>
<td>0.12</td>
<td>551</td>
<td>478</td>
<td>70</td>
<td>3</td>
<td>0.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ModSQuaD</td>
<td>173</td>
<td>122</td>
<td>47</td>
<td>4</td>
<td>0.16</td>
<td>174</td>
<td>154</td>
<td>18</td>
<td>2</td>
<td>0.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UPENN</td>
<td>374</td>
<td>304</td>
<td>67</td>
<td>3</td>
<td>0.10</td>
<td>371</td>
<td>327</td>
<td>43</td>
<td>1</td>
<td>0.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>7353</td>
<td>5719</td>
<td>1518</td>
<td>116</td>
<td>0.12</td>
<td>7227</td>
<td>6271</td>
<td>919</td>
<td>37</td>
<td>0.07</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 2. Characteristics of study subjects genotyped for the \textit{CASP8} D302H and \textit{CASP10} V410I polymorphisms

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>\textit{CASP8} D302H</th>
<th>\textit{CASP10} V410I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carriers</td>
<td>Total 7353</td>
<td>BRCA1 4844</td>
</tr>
</tbody>
</table>

Breast cancer
- not affected
  - no. 3302
  - age at censure, mean ±SD 43.0 ±12.6
- affected
  - no. 4051
  - age at event, mean ±SD 42.0 ±9.7

Ovarian cancer
- not affected
  - no. 6628
  - age at censure, mean ±SD 41.6 ±10.9
- affected
  - no. 725
  - age at event, mean ±SD 50.6 ±9.9

Table 3. Genotype distributions for the \textit{CASP8} D302H and \textit{CASP10} V410I polymorphisms

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>\textit{CASP8} D302H</th>
<th>\textit{CASP10} V410I</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCA1</td>
<td>Total 4844</td>
<td>GG 3784</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>not affected</td>
<td>2241</td>
</tr>
<tr>
<td></td>
<td>affected</td>
<td>2603</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>not affected</td>
<td>4268</td>
</tr>
<tr>
<td></td>
<td>affected</td>
<td>576</td>
</tr>
<tr>
<td>BRCA2</td>
<td>Total 2509</td>
<td>GG 1935</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>not affected</td>
<td>1061</td>
</tr>
<tr>
<td></td>
<td>affected</td>
<td>1448</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>not affected</td>
<td>2360</td>
</tr>
<tr>
<td></td>
<td>affected</td>
<td>149</td>
</tr>
</tbody>
</table>
Table 4. Association of CASP8 D302H with breast and ovarian cancer risk

<table>
<thead>
<tr>
<th>CASP8 D302H</th>
<th>hazard ratio (95%CI)</th>
<th>p-value&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>per rare allele</td>
<td>heterozygotes&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRCA1</td>
<td>0.85 (0.76-0.97)</td>
<td>0.83 (0.72-0.95)</td>
</tr>
<tr>
<td>BRCA2</td>
<td>1.06 (0.88-1.27)</td>
<td>1.04 (0.84-1.30)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRCA1</td>
<td>0.69 (0.53-0.89)</td>
<td>0.73 (0.55-0.98)</td>
</tr>
<tr>
<td>BRCA2</td>
<td>1.27 (0.73-2.23)</td>
<td>1.25 (0.67-2.34)</td>
</tr>
</tbody>
</table>

<sup>a</sup> versus common homozygotes  
<sup>b</sup> 2df test

Table 5. Association of CASP10 V410I with breast and ovarian cancer risk

<table>
<thead>
<tr>
<th>CASP10 V410I</th>
<th>hazard ratio (95%CI)</th>
<th>p-value&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>per rare allele</td>
<td>heterozygotes&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRCA1</td>
<td>0.98 (0.84-1.15)</td>
<td>0.94 (0.80-1.10)</td>
</tr>
<tr>
<td>BRCA2</td>
<td>1.03 (0.80-1.31)</td>
<td>1.06 (0.82-1.38)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRCA1</td>
<td>1.12 (0.83-1.52)</td>
<td>1.08 (0.78-1.52)</td>
</tr>
<tr>
<td>BRCA2</td>
<td>1.78 (1.01-3.12)</td>
<td>1.60 (0.85-2.98)</td>
</tr>
</tbody>
</table>

<sup>a</sup> versus common homozygotes  
<sup>b</sup> 2df test
**Figure 1.** Forest plots of the study-specific estimates of the per-allele hazard ratios for *CASP8* D302H in *BRCA1* mutation carriers (endpoints breast and ovarian cancer). The area of the squares is proportional to the inverse of the variance of the estimate. Horizontal lines represent the 95% confidence intervals. The vertical dashed line indicates the overall effect estimate.
Competing Interests

No competing interests were identified among the authors.

Acknowledgments

The CIMBA data management and genotyping is supported by Cancer Research –UK.

Epidemiological study of BRCA1 & BRCA2 mutation carriers (EMBRACE)


**Genetic Modifiers of cancer risk in BRCA1/2 mutation carriers study (GEMO)**

The GEMO study (Cancer Genetics Network "Groupe Génétique et Cancer", Fédération Nationale des Centres de Lutte Contre le Cancer, France) is supported by the Ligue National Contre le Cancer, Association for International Cancer Research Grant AICR-07-0454 and the Association "Le cancer du sein, parlons-en!" Award. LB is supported by Association for
International Cancer Research Grant AICR-07-0454. We wish to thank all the GEMO collaborating groups for their contribution to this study.

**German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC)**

GC-HBOC is supported by a grant of the German Cancer Aid (grant 107054) and the Center for Molecular Medicine Cologne (grant TV93) to RKS. We thank Juliane Köhler for her excellent technical assistance, D. Schäfer, Farnoosh Fathali-Zadeh, Claus R. Bartram, and the 12 clinical centers for providing samples and clinical data. GC-HBOC center for data management and biostatistics: Michael Brosig, Ute Enders, Marlies Herold, Markus Loeffler, Jan Schaefer, Marcus Wetzler, Kerstin Wieland, Silke Zachariae.

**The Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab)**

We wish to thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (funded by NHMRC grants 145684, 288704 and 454508) for their contributions to this resource, and the many families who contribute to kConFab. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia.

ABS and GCT are NHMRC Research Fellows.

**The Swedish BRCA1 and BRCA2 study (SWE-BRCA).**

SWE-BRCA collaborators: Per Karlsson, Margareta Nordling, Annika Bergman and Zakaria Einbeigi, Gothenburg, Sahlgrenska University Hospital; Marie
Stenmark-Askmalm and Sigrun Liedgren, Linkoping University Hospital; Ake Borg, Niklas Loman, Hakan Olsson, Ulf Kristoffersson, Helena Jernstrom, Katja Harbst and Karin Henriksson, Lund University Hospital; Annika Lindblom, Brita Arver, Anna von Wachenfeldt, Annelie Liljegren, Gisela Barbany-Bustinza, and Johanna Rantala, Stockholm, Karolinska University Hospital; Beatrice Malmer, Henrik Gronberg, Eva-Lena Stattin, and Monica Emanuelsson, Umea University Hospital; Hans Ehrencrona, Richard Rosenquist Brandell, and Niklas Dahl, Uppsala University Hospital. We thank the Swedish Cancer Society.

The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)

HEBON Collaborating Centers: Coordinating center: Netherlands Cancer Institute, Amsterdam: Frans Hogervorst, Senno Verhoef, Anouk Pijpe, Laura van ‘t Veer, Flora van Leeuwen, Matti Rookus; Erasmus Medical Center, Rotterdam: Margriet Collée, Ans van den Ouweland, Mieke Kriege, Mieke Schutte, Maartje Hooning, Caroline Seynaeve; Leiden University Medical Center, Leiden: Christi van Asperen, Juul Wijnen, Maaike Vreeswijk, Peter Devilee, Rob Tollenaar; Radboud University Nijmegen Medical Center, Nijmegen: Nicoline Hoogerbrugge, Marjolijn Ligtenberg; University Medical Center Utrecht, Utrecht: Margreet Ausems, Rob B. van der Luijt; Amsterdam Medical Center: Cora Aalfs, Theo van Os; VU University Medical Center, Amsterdam: Hanne Meijers-Heijboer, Hans Gille; University Hospital Maastricht, Maastricht: Encarna Gomez-Garcia, Rien Blok. The HEBON study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI 2007-3756.

University of Pennsylvania (UPENN) study.
K.L.N. is supported by the Breast Cancer Research Foundation (BCRF). S.M.D. is supported by QVC Network, the Fashion Footwear Association of New York, and the Marjorie B. Cohen Foundation.

**Spanish National Cancer Centre (CNIO).**

Thanks to Rosario Alonso, Alicia Barroso, and Guillermo Pita for their technical support. The samples studied at the CNIO were recruited by the Spanish Consortium for the Study of Genetic Modifiers of BRCA1 and BRCA2 (Spanish National Cancer Centre [Madrid], Sant Pau Hospital [Barcelona], Instituto Catalad Oncologia [Barcelona], Valladolid University [Valladolid], Cancer Research Centre [Salamanca], and Instituto Dexeus [Barcelona]) and the Instituto Demokritos (Greece). The work carried out at the CNIO was partly funded by grants from the Genome Spain Foundation, Mutual Madrilena/06, Asociación Española Contra el Cancer/08, Ministry of Health FIS061090 and RD06/0020/1060, and Ministry of Science and Innovation PI081120.

**Sheeba Medical Center Study (SMC)**

The SMC study was supported in part by the Israel Cancer Association (ICA)

**National Cancer Institute study (NCI)**

We acknowledge the contributions of Dr. Jeffery A. Struwing and Marbin A Pineda from the NCI Laboratory of Population Genetics. Drs. Mai and Greene were supported by funding from the Intramural Research Program of the National Cancer Institute, Division of Cancer Epidemiology and Genetics. Their data collection efforts were supported by NIH Support Services Contracts NO2-CP-11019-50 and N02-CP-65504 with Westat, Inc, Rockville, MD.
Helsinki Breast Cancer Study (HEBCS):

Heli Nevanlinna, Tuomas Heikkinen, Carl Blomqvist, Kirsimari Aaltonen, Kristiina Aittomaki, Helsinki University Central Hospital, Helsinki, Finland.

HEBCS wishes to thank Drs. Kirsimari Aaltonen and Carl Blomqvist and RN Hanna Jäntti for their help with the patient data and Tuomas Heikkinen and Kati Kämpjärvi for their help with the genetic analysis. HEBCS gratefully acknowledges the Finnish Cancer Registry for the cancer data. The HEBCS study has been financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland [132473], the Finnish Cancer Society and the Sigrid Juselius Foundation.

MoDSquaD

C.I.S. is supported by the Mayo Rochester Early Career Development Award for Non-Clinician Scientists. We acknowledge the contributions of Petr Pohlreich and Zdenek Kleibl (Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic) and the support of the Grant Agency of the Czech Republic, project No. GP301/08/P103 (to M.Z.). We acknowledge the contribution of Kim De Leeneer and Anne De Paepe. This research was supported by grant 1.5.150.07 from the Fund for Scientific Research Flanders (FWO) to Kathleen Claes and by grant 12051203 from the Ghent university to Anne De Paepe. Bruce Poppe is Senior Clinical Investigator of the Fund for Scientific Research of Flanders (FWO - Vlaanderen). Kim De Leeneer is supported by the Vlaamse Liga tegen Kanker through a grant of the Foundation Emmanuel van der Schueren. L.F., Machackova Eva, and Lukesova Miroslava's are supported through the Ministry of Health grant CR-MZ0 MOU 2005.

Hospital Clinico San Carlos (HCSC).
Trinidad Caldes and Miguel de la Hoya were supported by a FMMA/06; FIS 05/0864 and RD06/0020/0021 (RTICC; ISCIII) Spanish Ministry of Science and Innovation.

_Mayo Clinic Study (MAYO)_

The Mayo Clinic study was supported in part by the Breast Cancer Research Foundation (BCRF), a grant from Susan G. Komen for the Cure, the Mayo Clinic Breast Cancer SPORE (P50-CA116201) and NIH grants CA122340 and CA128978 to FJC.

_Interdisciplinary Health Research International Team Breast Cancer susceptibility (INHERIT)_

Jacques Simard, Francine Durocher, Rachel Laframboise, Marie Plante, Centre Hospitalier Universitaire de Quebec & Laval University, Quebec, Canada ; Peter Bridge, Jilian Parboosingh, Molecular Diagnostic Laboratory, Alberta Children’s Hospital, Calgary, Canada; Jocelyne Chiquette, Hôpital du Saint-Sacrement, Quebec, Canada ; Bernard Lesperance, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada. JS is Chairholder of the Canada Research Chair in Oncogenomics. This work was supported by the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program. This work was supported by the Canadian Breast Cancer Research Alliance-grant #019511.

_Ontario Cancer Genetics Network Study (OCGN)_

We wish to thank Mona Gill, Nayana Weerasooriya and members of the Ontario Cancer Genetics Network for their contributions to the study. We acknowledge funding from Cancer Care Ontario and the Canadian Institutes of Health Research for the “CIHR Team of Prediction and Communication of Familial Risks of Breast Cancer” program.
Fox Chase Cancer Center (FCCC).

We thank Ms. JoEllen Weaver and Mr. John Malick for expert technical assistance. A.K.G. was funded by SPORE P50 CA83638, U01 CA69631, 5U01 CA113916, and the Eileen Stein Jacoby Fund.

Deutsches Krebsforschungszentrum study (DKFZ)

We thank Antje Seidel-Renkert for expert technical assistance. The study was supported by the DKFZ.

Pisa Breast Cancer Study (PBCS)

PBCS acknowledges AIRC the Italian Association for Cancer Research.
References


